Akston Launches Clinical Trial for Novel Canine Cancer Therapy
Akston Biosciences Corporation has partnered with Purdue University to develop a drug targeting PD-L1 in dogs with solid tumors.
The clinical study will evaluate a first-in-class immuno-enhancing therapy supported by the proprietary Fc-fusion protein platform Ambifect.
The intramuscular injection therapy targets PD-L1 in dogs with solid tumors.
- Partnership: Akston Biosciences Corporation and Purdue University
- Location: West Lafayette, Indiana, and its College of Veterinary Medicine
- First patient: Rocco, an 11-year-old Dutch shepherd dog
Akston Biosciences Corporation launched the study with Rocco receiving the first dose of the trial therapy.
Akston Biosciences Corporation develops innovative therapies.